Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis

Laboratory Investigation

Volumn 97, Issue 7, 2017, Pages 806-818

  Wermuth, Peter J ^a   Carney, Kellan R ^a   Mendoza, Fabian A ^a   Piera Velazquez, Sonsoles ^a   Jimenez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CORN OIL; CRE RECOMBINASE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; VASCULAR ENDOTHELIAL CADHERIN; HYDROXYPROLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RETRIEVAL; ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; FIBROSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; LIVER FIBROSIS; LUNG FIBROSIS; MALE; MICROVASCULATURE; MOUSE; MOUSE STRAIN; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SKIN FIBROSIS; VASCULAR FIBROSIS; VASCULARIZATION; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; GENETICS; LUNG; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ENDOTHELIAL CELLS; FEMALE; FIBROSIS; HYDROXYPROLINE; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; ORGAN SPECIFICITY; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 85021799132     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2017.23     Document Type: Article

References (40)

1. Varga J, Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-567.
2. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
3. McCray CJ, Mayes MD. Update on systemic sclerosis. Curr Allergy Asthma Rep 2015;15:25.
4. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-1040.
5. Wei J, Bhattacharyya S, Tourtellotte WG, et al. Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy. Autoimmun Rev 2011;10:267-275.
6. Pattanaik D, Brown M, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol 2015;6:272.
7. Stern EP, Denton CP. The pathogenesis of systemic sclerosis. Rheum Dis Clin North Am 2015;41:367-382.
8. Campbell RM, LeRoy EC. Pathogenesis of systemic sclerosis: A vascular hypothesis. Semin Arthritis Rheum 1975;4:351-368.
9. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22:675-694.
10. Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008;34:41-55.
11. Kahaleh B. Vascular disease in scleroderma: Mechanisms of vascular injury. Rheum Dis Clin North Am 2008;34:57-71.
12. Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 2010;6:453-460.
13. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013;65: 1953-1962.
14. Altorok N, Wang Y, Kahaleh B. Endothelial dysfunction in systemic sclerosis. Curr Opin Rheumatol 2014;26:615-620.
15. Pattanaik D, Brown M, Postlethwaite AE. Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res 2011;4:105-125.
16. Van Linthout S, Miteva K, Tschope C. Crosstalk between fibroblasts and inflammatory cells. Carciovasc Res 2014;102:258-269.
17. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, pulmonary vascular remodeling. J Am Coll Cardiol 2009;54 (1 Suppl):S10-S19.
18. Chizzolini C, Brembilla NC, Montanari E, et al. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011;10:276-281.
19. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: One function, multiple origins. Am J Pathol 2007;170:1807-1816.
20. McAnulty RJ. Fibroblasts and myofibroblasts: Their source, function and role in disease. Int J Biochem Cell Biol 2007;39:666-671.
21. Hinz B, Phan SH, Thannickal VJ, et al. Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. Am J Pathol 2012;180:1340-1355.
22. Kramann R, DiRocco DP, Humphreys BD. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment in fibrotic disease. J Pathol 2013;231:273-289.
23. Sporn MB, Roberts AB, Wakefield LM, et al. Transforming growth factor-beta: Biological function and chemical structure. Science 1986;233:532-534.
24. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987;247:597-604.
25. Lafyatis R. Transforming growth factor-at the centre of systemic sclerosis. Nat Rev Rheumatol 2014;10:706-719.
26. Varga J, Whitefield ML. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci 2009;1:226-235.
27. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: Key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-511.
28. Kawakami T, Ihn H, Xu W, et al. Increased expression of TGF-beta receptors by scleroderma fibroblasts: Evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
29. Pannu J, Gore-Hyer E, Yamanaka M, et al. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinasedeficient transforming growth factor beta receptor type II in scleroderma. Arthritis Rheum 2004;50:1566-1577.
30. Wermuth PJ, Li Z, Mendoza FA, et al. Stimulation of transforming growth factor-1-induced endothelial-to-mesenchymal transtition and tissue fibrosis by endothelin-1 (ET-1): A novel profibrotic effect of ET-1. PLoS ONE 2016;11:e0161988.
31. Sonnylal S, Denton CP, Zheng B, et al. Postnatal induction of transforming growth factor signaling in fibroblasts of mice recapitulates clinical, histologic, biochemical features of scleroderma. Arthritis Rheum 2007;56:334-344.
32. Alva JA, Zovein AC, Monvoisin A, et al. VE-Cadherin-Cre-recombinase transgenic mouse: A tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn 2006;235:759-767.
33. Monvoisin A, Alva JA, Hofmann JJ, et al. VE-cadherin-CreERT2 transgenic mouse: A model for inducible recombination in the endothelium. Dev Dyn 2006;235:3413-3422.
34. Del Galdo F, Sotgia F, de Almeida CJ, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008;58:2854-2865.
35. Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta 1967;18:267-273.
36. Edwards CA, O'Brien Jr. WD. Modified assay for determination of hydroxyproline in a tissue hydrolysate. Clin Chim Acta 1980;104:161-167.
37. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60:1508-1518.
38. Mendoza FA, Piera-Velazquez S, Farber JL, et al. Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 2016;68:210-217.
39. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 2011;179:1074-1084.
40. Jimenez SA. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol 2013;2013:835948.